Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenrispodun in Idiopathic Parkinson's Disease
NCT03257046Phase 2Completed
- Sponsor
- Intra-Cellular Therapies
- Start
- Sep 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lenrispodun in Parkinson's disease (PD) (6 arms), sponsored by Intra-Cellular Therapies. Primary endpoint: Number of patients with reported or observed treatment-related adverse events at 7 days. Started Sep 2017; status: completed.
02
Drugs
lenrispodun
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03257046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03257046.